PD-1 Antibody – 148Nd

Catalog: 714801                                           Clone: D4W2J                                            Isotype: Rabbit IgG
Reactivity: Human*
Storage: PD-1 antibody is supplied in antibody stabilizer with 0.05% sodium azide. Store a 4°C

IHC: PD-1 antibody staining of FFPE human tonsil

MIBI: PD-1 antibody staining (cyan) of FFPE human tonsil, counterstained with dsDNA (magenta)

IHC: PD-1 antibody staining of FFPE human liver

MIBI: PD-1 antibody staining (cyan) of FFPE human liver, counterstained with dsDNA (magenta)

Background: PD-1 (programmed cell death protein 1, CD279) is expressed on activated T cells and binds to PD-L1 and PD-L2 to inhibit T cell activation through recruitment of phosphatases that attenuate TCR signaling. The interaction between PD-1 and PD-L1 supports tolerance to self-antigens and contributes to the healthy down-regulation of immune activation following viral clearance. In cancer the PD-1/PD-L1 interaction is exploited by tumor cells to dampen an immune response from tumor-infiltrating lymphocytes and as such these immune checkpoint molecules are being actively targeted by immuno-oncology therapies.

Validation: Each lot of conjugated PD-a antibody is quality control tested by MIBIscope™ analysis of stained tissue microarray using the appropriate positive and negative tissue field of views and are pathologist verified.

Recommended Usage: 1 uL of PD-1 antibody per 100 uL staining volume using the MIBI™ Staining Protocol.
For optimal results, antibody should be titrated for each desired application.  Suggested starting range is 1:100.

MIBI technology: Learn more about MIBI Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.


  • Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response
    Biomarkers and Combinations. Science translational medicine. 2016; 8(328):328rv4.

* Conjugate tested on human tissue.

Contact Us

Let us know how we can help you.

    Immuno-oncology/CancerNeuroscienceInfectious DiseaseImmunologyStem CellOther


    Please contact me. I understand that I can choose to unsubscribe at any time by e-mailing marketing@ionpath.com.

    Contact Us

    We are using cookies on our website

    Please confirm, if you accept our tracking cookies. You can also decline the tracking and continue to visit our website without any data sent to third-party services.